Neogap Therapeutics partners with NorthX Biologics to advance scalable manufacturing for its novel cancer cell therapy

Neogap Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy. Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.

Neogap Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumours by training the immune system to recognise and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.

The collaboration, carried out within the framework of the EIC Accelerator program, aims to establish a robust, cost-effective production setup that enhances both productivity and scalability.

The project includes a comprehensive analysis of Neogap’s manufacturing protocols, with a focus on scale-out strategies and GMP process industrialisation to support large-scale clinical trials and eventual commercialisation. The goal is to implement streamlined production processes and logistics, increasing resilience and cost-effectiveness as Neogap progresses toward broader clinical applications and greater patient access.

Samuel Svensson, CEO of Neogap Therapeutics, comments: “Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance.”

Janet Hoogstraate, CEO of NorthX Biologics, comments: “At NorthX Biologics, we are proud to be ‘beyond CDMO’ – a proactive partner that actively contributes to the development of future medicines by collaborating with innovative companies like Neogap Therapeutics. Through our close partnership, we leverage our expertise and Innovation Hub to support at every stage, from initial concept to scalable production of pioneering cell therapies. Together, we are driving groundbreaking innovations forward to improve patients’ lives around the world.”

About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. EpiTCer® is used to multiply T cells that can recognise and attack the selected tumor-specific targets. Neogap is located at the Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company’s website at neogap.se and follow Neogap on LinkedIn.

Project reference number: 190185439 – NEOpTTL

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.